Supercharged immune cells take on tough ovarian cancers
NCT ID NCT06483048
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new treatment for people with ovarian cancer that has returned or is resistant to standard platinum chemotherapy. The treatment uses a patient's own immune cells (T cells), which are trained in a lab to recognize and attack a protein called MUC1 found on cancer cells. The main goals are to find the safest dose and see if the therapy can shrink tumors. About 12 participants will be enrolled at Mayo Clinic.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Mayo Clinic in Arizona
RECRUITINGScottsdale, Arizona, 85259, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Targeted pill aims to halt recurrent ovarian and endometrial cancers
- Vaccine-Immunotherapy combo takes aim at Hard-to-Treat ovarian cancer
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- Engineered immune cells take aim at Hard-to-Treat cancers
- Immune cells retrained to hunt ovarian cancer in new trial
- New hope for Platinum-Resistant ovarian cancer: ONC201 and paclitaxel combo trial launches